Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze GKOS Glaukos Corporation. Please read: https://finlab.finance/en/setup?stock=GKOS

No install, open FinLab Studio

GKOS

Glaukos Corporation Healthcare As of 2026-07-31 Updated daily after market close

quality needs a look, discounted valuation.

4 active signals
52-week adjusted-price high Top-quintile 6-month momentum Filed revenue acceleration EPS surprise beat
This page refreshes daily after the close. Add Glaukos Corporation to your watchlist to track signal changes on your next visit.
Valuation 48Quality 25Growth 80Momentum 90Risk / liquidity 67

Is Glaukos Corporation a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 23th percentile. TTM ROE is about -28.2%.

  • Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 55th percentile. Average 20-day dollar volume is about $137.0M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

20 historical occurrences (since 2017-01-12)
Average forward return after 52-week adjusted-price high。20-day: Win 65%, Sample 20, Median +4.03%, Excess +1.74%, Beat mkt rate 60%；60-day: Win 78.9%, Sample 19, Median +12.24%, Excess +3.61%, Beat mkt rate 68.4%；120-day: Win 72.2%, Sample 18, Median +12.54%, Excess +1.04%, Beat mkt rate 61.1%

120 days after: historical avg +6.74%

20-day +3.21%
60-day +6.85%
120-day +6.74%
20-day
60-day
120-day
Win
65%
78.9%
72.2%
Sample
20
19
18
Median
+4.03%
+12.24%
+12.54%
Excess
+1.74%
+3.61%
+1.04%
Beat mkt rate
60%
68.4%
61.1%

Over 18 occurrences, 120-day forward avg gained 6.74%, beat the market by 1.04 pts; win rate 72.2%.

Top-quintile 6-month momentum

Active · now 86.46808510638297%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

28 historical occurrences (since 2016-07-14)
Average forward return after Top-quintile 6-month momentum。20-day: Win 70.4%, Sample 27, Median +8.36%, Excess +2.23%, Beat mkt rate 66.7%；60-day: Win 63%, Sample 27, Median +10.53%, Excess +4.81%, Beat mkt rate 59.3%；120-day: Win 46.2%, Sample 26, Median -3.77%, Excess -2.94%, Beat mkt rate 50%

120 days after: historical avg +1.86%

20-day +3.03%
60-day +8.03%
120-day +1.86%
20-day
60-day
120-day
Win
70.4%
63%
46.2%
Sample
27
27
26
Median
+8.36%
+10.53%
-3.77%
Excess
+2.23%
+4.81%
-2.94%
Beat mkt rate
66.7%
59.3%
50%

Over 26 occurrences, 120-day forward avg gained 1.86%, lagged the market by 2.94 pts; win rate 46.2%.

Filed revenue acceleration

Active · now 36.29608205219481%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

16 historical occurrences (since 2019-02-28)
Average forward return after Filed revenue acceleration。20-day: Win 56.2%, Sample 16, Median +2.01%, Excess -1.07%, Beat mkt rate 50%；60-day: Win 62.5%, Sample 16, Median +7.67%, Excess +1.05%, Beat mkt rate 56.2%；120-day: Win 35.7%, Sample 14, Median -9.45%, Excess -4.24%, Beat mkt rate 42.9%

120 days after: historical avg +1.2%

20-day +0.61%
60-day +5.6%
120-day +1.2%
20-day
60-day
120-day
Win
56.2%
62.5%
35.7%
Sample
16
16
14
Median
+2.01%
+7.67%
-9.45%
Excess
-1.07%
+1.05%
-4.24%
Beat mkt rate
50%
56.2%
42.9%

Over 14 occurrences, 120-day forward avg gained 1.2%, lagged the market by 4.24 pts; win rate 35.7%.

EPS surprise beat

Active · now 33.50432221905575%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

30 historical occurrences (since 2015-11-10)
Average forward return after EPS surprise beat。20-day: Win 39.3%, Sample 28, Median -4.16%, Excess -3.58%, Beat mkt rate 28.6%；60-day: Win 57.1%, Sample 28, Median +7.68%, Excess +4.92%, Beat mkt rate 57.1%；120-day: Win 55.6%, Sample 27, Median +10.5%, Excess +6.77%, Beat mkt rate 55.6%

120 days after: historical avg +12.95%

20-day -1.9%
60-day +8.68%
120-day +12.95%
20-day
60-day
120-day
Win
39.3%
57.1%
55.6%
Sample
28
28
27
Median
-4.16%
+7.68%
+10.5%
Excess
-3.58%
+4.92%
+6.77%
Beat mkt rate
28.6%
57.1%
55.6%

Over 27 occurrences, 120-day forward avg gained 12.95%, beat the market by 6.77 pts; win rate 55.6%.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.